| Nov 7 |
Vaxart to Host Third Quarter 2024 Business Update and Financial Results Conference Call on November 13
|
| Oct 31 |
Investing in Vaxart (NASDAQ:VXRT) five years ago would have delivered you a 127% gain
|
| Oct 24 |
Vaxart to Showcase its COVID-19 and Norovirus Oral Pill Vaccine Candidates at World Vaccine Congress Europe 2024
|
| Oct 15 |
Vaxart to Present Norovirus Data at IDWeek 2024 Underscoring Commitment to Address Significant Unmet Need
|
| Oct 9 |
Vaxart Inc (VXRT) Q2 2024 Earnings Call Highlights: Revenue Surge and Strategic Advances
|
| Sep 30 |
Vaxart Announces Initiation of Sentinel Cohort for Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate
|
| Aug 28 |
Vaxart Announces Publication in Vaccines of Preclinical Data Supporting the Potential of its Mucosal Vaccine Technology Platform in Enabling Therapeutic Vaccination for HPV-Related Cervical Dysplasia
|
| Aug 15 |
Oppenheimer starts Vaxart at outperform, cites oral vaccine focus
|
| Aug 15 |
Oral Vaccine Focused Penny Stock Vaxart Is 'Uniquely Positioned', Analyst Sees Almost 83% Upside
|
| Aug 11 |
Vaxart Second Quarter 2024 Earnings: Misses Expectations
|
